StocksMedium•18 November 2026•
1 min read
CSPC Pharmaceutical Profit Jumps 101.5% on AstraZeneca Licensing Income

Key Facts
1CSPC Pharmaceutical Group reported a 101.5% surge in 9-month net profit, driven by license income from AstraZeneca.
2The company's revenue grew by 27% during the same period, supported by finished-drug sales.
CSPC Pharmaceutical Group reported a 101.5% surge in net profit for the first nine months of 2026, driven by license income from AstraZeneca. TradingView reported that the company's revenue grew by 27% during the same period, supported by robust finished-drug sales.
CSPC Pharmaceutical (1093.HK) closed at HKD 7.89 on November 17, 2026, while AstraZeneca (AZN) closed at $182.27 on the same date. The growth in core segments helped offset declines in bulk products and functional foods caused by pricing competition and procurement pressures.